Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

2015131 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: Annals of Oncology

Volume 27, Issue 3, pp. 417-423

Field-Weighted Citation Impact: 15.78